| scholarly article | Q13442814 |
| P50 | author | Ennio Giulio Favalli | Q51741925 |
| Martina Biggioggero | Q60319740 | ||
| P2093 | author name string | Federica Mesina | |
| P2860 | cites work | Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases | Q26778600 |
| The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 | ||
| Tools for the Assessment of Comorbidity Burden in Rheumatoid Arthritis. | Q54965764 | ||
| Most people over age 50 in the general population do not meet ACR remission criteria or OMERACT minimal disease activity criteria for rheumatoid arthritis | Q80091681 | ||
| TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice | Q84565491 | ||
| Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis | Q94174915 | ||
| A new method of classifying prognostic comorbidity in longitudinal studies: development and validation | Q29547376 | ||
| Rheumatoid arthritis. | Q30244019 | ||
| Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry. | Q31021097 | ||
| Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry. | Q31153194 | ||
| Comorbidity measures for use with administrative data | Q32144770 | ||
| Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries | Q33365103 | ||
| Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity | Q34238357 | ||
| Treating rheumatoid arthritis to target: recommendations of an international task force | Q34462557 | ||
| Impact of age and comorbidities on the criteria for remission and response in rheumatoid arthritis | Q35556054 | ||
| Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial | Q35605449 | ||
| Older age at rheumatoid arthritis onset and comorbidities correlate with less Health Assessment Questionnaire-Disability Index and Clinical Disease Activity Index response to etanercept in the RADIUS 2 registry | Q36028729 | ||
| Comparisons between comorbid conditions and health care consumption in rheumatoid arthritis patients with or without biological disease-modifying anti-rheumatic drugs: a register-based study. | Q36220832 | ||
| Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis | Q36464352 | ||
| Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis | Q37177578 | ||
| Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). | Q37465556 | ||
| Co-morbidities in established rheumatoid arthritis. | Q37964309 | ||
| Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study | Q38667206 | ||
| Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative | Q38777496 | ||
| Comorbidities in rheumatoid arthritis | Q38793526 | ||
| Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis | Q39180660 | ||
| The role of methotrexate as combination therapy with etanercept in rheumatoid arthritis: Retrospective analysis of a local registry. | Q39341401 | ||
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update | Q40305889 | ||
| The impact of multimorbidity status on treatment response in rheumatoid arthritis patients initiating disease-modifying anti-rheumatic drugs | Q40748946 | ||
| Development of a multimorbidity index: Impact on quality of life using a rheumatoid arthritis cohort | Q41549484 | ||
| Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study | Q42641063 | ||
| Prevalence and predictive factors of comorbidity in rheumatoid arthritis patients monitored prospectively from disease onset up to 20 years: lack of association between inflammation and cardiovascular disease | Q44051899 | ||
| Chronic inflammation and low-dose glucocorticoid effects on glucose metabolism in premenopausal females with rheumatoid arthritis free of conventional metabolic risk factors. | Q45325996 | ||
| Validation of the rheumatic disease comorbidity index | Q46366513 | ||
| Generalizability of Patients With Rheumatoid Arthritis in Biologic Agent Clinical Trials. | Q48064243 | ||
| Presence of comorbidity affects both treatment strategies and outcomes in disease activity, physical function, and quality of life in patients with rheumatoid arthritis | Q48069664 | ||
| Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics. | Q48122799 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| rheumatism | Q684924 | ||
| comorbidity | Q1414874 | ||
| P304 | page(s) | 6107217 | |
| P577 | publication date | 2019-01-10 | |
| P1433 | published in | BioMed Research International | Q17509958 |
| P1476 | title | The Use of Rheumatic Disease Comorbidity Index for Predicting Clinical Response and Retention Rate in a Cohort of Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Alpha Inhibitors | |
| P478 | volume | 2019 |
| Q94591396 | Prevalence and pattern of comorbidities in chronic rheumatic and musculoskeletal diseases: the COMORD study | cites work | P2860 |
Search more.